AptarGroup, Inc.

AptarGroup, Inc.

126.90
EUR
+0.60
(+0.48%)
Feb 18Next Earn
AptarGroup, Inc.
HAN:AGT
(Hannover Stock Exchange)

Recent

price

126.90

P/E

ratio

- -

div

yld

1.01%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
30.84
35.12
35.11
38.13
39.96
37.02
37.11
39.55
44.28
44.98
45.47
49.15
50.8
53.15
54.01
57.46
- -
Revenue per Share
2.58
2.76
2.45
2.6
2.95
3.19
3.27
3.52
3.12
3.81
3.32
3.72
3.66
4.34
5.65
5.97
- -
Basic EPS, GAAP
4.13
3.92
4.73
4.32
4.87
5.17
5.14
5.2
5.01
8.02
8.76
5.53
7.24
8.67
9.43
8.59
- -
Free Cash Flow per Basic Share
0.66
0.8
0.88
1
1.09
1.14
1.22
1.28
1.32
1.42
1.44
1.5
1.52
1.58
1.72
1.84
1.45
Dividend per Share
19.15
19.57
20.94
22.63
17.8
18.39
18.9
21.23
22.62
24.64
28.47
30.07
31.5
35
37.17
41.55
41.25
Book Value per Share
15.67
15.96
14.82
16.38
11.83
12.92
10.82
12.5
7.24
8.11
9.35
9.66
12.16
16.09
19.26
20.79
20.87
Tangible Book Value per Share
67
67
66
66
65
63
63
62
62
64
64
66
65
66
66
66
64
Basic Weighted Avg Shares
2,077
2,337
2,331
2,520
2,598
2,317
2,331
2,469
2,765
2,860
2,929
3,227
3,322
3,487
3,583
3,777
- -
Sales/Revenue/Turnover
12.91
12.28
11.24
11.76
11.8
13.99
13.46
13.19
12.66
13.71
12.49
11.48
11.61
12.88
14.22
13.53
- -
Operating Margin (%)
133
134
137
150
152
139
155
153
172
195
220
235
234
249
264
287
- -
Depreciation Expense
173
184
163
172
192
199
206
220
195
242
214
244
239
284
375
393
- -
Net Income, GAAP
31.76
33.21
32.71
34.97
33.07
32.34
26.7
25.37
26.79
29.19
28.91
24.25
28.43
24.18
20.35
20.12
- -
Effective Tax Rate (%)
8.35
7.86
6.98
6.83
7.38
8.6
8.82
8.91
7.04
8.47
7.31
7.56
7.2
8.16
10.45
10.4
- -
Profit Margin (%)
641
625
584
656
609
883
727
1,142
642
608
589
376
513
298
410
727
614
Working Capital
259
255
353
355
589
761
773
1,191
1,126
1,141
1,107
955
1,096
726
738
1,187
1,068
LT Debt
1,280
1,291
1,380
1,480
1,104
1,150
1,174
1,312
1,423
1,572
1,851
1,985
2,068
2,321
2,486
2,712
2,661
Total Equity
11.4
11.46
9.89
9.81
10.49
11.23
11.26
10.31
7.95
9.52
8.2
8.36
8.35
9.05
11.24
10.3
- -
Return on Invested Capital (%)
11.36
11.61
9.93
9.8
10.5
11.39
11.32
10.67
8.28
9.66
8.06
8.48
8.23
9.29
11.6
11.15
- -
Return on Capital (%)
13.7
14.3
12.18
12.03
14.84
17.7
17.7
17.7
14.24
16.18
12.51
12.78
11.89
13.05
15.68
15.28
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
222
- -
351
LT Borrowings
1,143
- -
1,025
LT Finance Leases
44
- -
43
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
64
63
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,768
- -
1,837
Cash, Cash Equivalents & STI
229
- -
212
Accounts Receivable, Net
833
- -
884
Inventories
551
- -
583
Total Current Liabilities
1,063
- -
1,223
Payables & Accruals
841
- -
872
ST Debt
222
- -
351
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.04%
7.97%
9.1%
Free Cash Flow
8.53%
3.03%
-9.71%
Net Income, GAAP
7.89%
13.5%
4.87%
Sales/Revenue/Turnover
5.06%
5.25%
5.42%
Total Cash Common Dividend
5.46%
5.48%
5.9%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
915
910
909
848
3,583
2025
887
966
961
963
3,777
2026
983
- -
1,019
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.26
1.36
1.51
1.52
5.65
2025
1.19
1.69
1.95
1.14
5.97
2026
1.13
- -
0.51
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
0.41
0.45
0.45
1.72
2025
0.45
0.45
0.45
0.48
1.84
2026
0.48
- -
0.48
- -
- -
Business
AptarGroup, Inc. designs, manufactures and markets a broad range of drug delivery systems, consumer product dispensing systems, active material science solutions and sealing, packaging services for the pharmaceutical, beauty, personal care, home care, food and beverage industries worldwide. The company operates through three main segments: Aptar Pharma, which provides nasal and pulmonary drug delivery devices including pumps for nasal allergy treatments, metered-dose inhaler valves for respiratory conditions such as asthma and chronic obstructive pulmonary disease, elastomers for injectable packaging components, proprietary Unidose and Bidose intranasal delivery systems, aerosol valves, digital health solutions and clinical trial materials manufacturing services; Aptar Beauty, which offers dispensing pumps, closures, pouch spouts, spray pumps and valves for fragrance, make-up, skincare and cleansing products; and Aptar Closures, which supplies dispensing closures, dosing cups, droppers and other packaging solutions. AptarGroup sells its products primarily in North America, Europe, Asia and Latin America; the company was incorporated in 1992 and maintains headquarters in Crystal Lake, Illinois, with manufacturing facilities and over 13,000 employees across 20 countries. Recently, Aptar Pharma acquired the device technology assets of SipNose Nasal Delivery Systems in November 2025 to expand its intranasal drug delivery portfolio for local, systemic and central nervous system indications including nose-to-brain pathways; acquired clinical trial materials manufacturing capabilities of Mod3 Pharma in July 2025 to enhance Phase 1 and 2 formulation, fill-finish services for orally inhaled and nasal drug products at an FDA-inspected facility in Boonton, New Jersey; acquired Brazilian pharmaceutical packaging firm Sommaplast in December 2025 to strengthen oral dosing solutions such as closures, droppers, dispensers and dosing cups amid growth in over-the-counter and nutraceutical markets; issued approximately $600 million in senior unsecured notes due 2031 in November 2025 to bolster financial flexibility for operations and acquisitions; and extended collaboration with Nasus Pharma on intranasal epinephrine devices.

Company News

  • Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium

  • Atrium Therapeutics Reports Third Quarter 2026 Financial Results

  • SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AptarGroup, Inc. (NYSE: ATR)

  • Dividend Champion, Contender, And Challenger Highlights: Week of November 8

  • Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting

  • Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)

  • Investing in AptarGroup (ATR)? Don't Miss Assessing Its International Revenue Trends

  • Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026

  • Aptar: 3 Key Takeaways for Long-Term Investors

  • Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November

  • Dividend Champion, Contender, And Challenger Highlights: Week November 1

  • AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript

  • What AptarGroup (ATR) Said on Its Q3 Earnings Call

  • AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates

  • Aptar Reports Third Quarter 2026 Results

  • Aptar Increases Quarterly Dividend to $0.50 Per Share

  • Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program

  • AptarGroup, Inc. $ATR Stock Bought by State of Alaska Department of Revenue

  • AptarGroup, Inc. (ATR) – What Are Brokerages Saying About This Stock?

  • AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner